Di Yi Cai Jing·2026-03-02 08:01Core Viewpoint - The competition in the GLP-1 diabetes and weight loss drug market is intensifying, prompting Novo Nordisk to adopt aggressive pricing strategies, including significant price adjustments in both the U.S. and China markets [1] Pricing Strategy - Novo Nordisk plans to implement substantial price changes in the U.S. market by 2027, while in China, a price reduction of approximately 20% for oral semaglutide has already been announced [1] Market Demand - The price adjustments coincide with a peak in public demand for weight management and blood sugar control post-holiday, leading to a surge in retail activity [1] - According to Meituan's latest data, the search and order volumes for related drugs have significantly increased, with semaglutide's search volume rising by 90% compared to pre-holiday levels [1] Competitive Landscape - The GLP-1 market is entering a new phase characterized by "price for volume" strategies, with online platforms emerging as a key battleground for these consumer-driven drugs [1] - This healthy competition is expected to reduce the long-term medication burden for patients and enhance the accessibility of quality drugs, driving the industry towards a more mature and inclusive direction [1]